The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related Thrombocytopenia

Assiut University

Status: Unknown

Conditions: Hepatitis C

Treatments: Drug: sofosbuvir daclatasvir; Drug: Ledipasvir/sofosbuvir

Study type: Interventional

Funder types: Other

Identifiers

NCT03169348

HCV

Details and patient eligibility

About

Autoimmune thrombocytopenic purpura is an immunological disorder characterized by increased platelet destruction due to presence of anti-platelet antibodies. Hepatitis C virus infection, which is one of the most common chronic viral infections worldwide, may cause secondary chronic immune thrombocytopenic purpura. It seemed to play a pathogenic role in autoimmune thrombocytopenic purpura. Moreover, the successful response (negative hepatitis C virus - ribonucleic acid) to tapered steroids and antiviral therapy was useful to revert thrombocytopenia

Enrollment: 50 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hepatitis C virus infection and thrombocytopenia before treatment

Exclusion criteria

• Infection Hepatitis B virus
• Hypersplenism
• Diseases affecting Bone marrow
• Major clotting factors abnormalities eg. Disseminated intravascular coagulopathy, severe Prothrombin deficiency

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

study group

Experimental group

Description:

Hepatitis- C virus with thrombocytopenia

Treatment:

Drug: sofosbuvir daclatasvir

Drug: Ledipasvir/sofosbuvir